Select a Region North America

UK Life Sciences Vision 10-Year Strategy Outlines 7 Missions to Solve Major Health Problems

Date: July 9, 2021 | Country: UNITED KINGDOM | Region: EUROPE | Type: Editor’s ChoicePolicy | Keywords: #acceleratedapproval #cardiovasculardisease #covid19 
#covidvaccinetaskforce #dementia #innovation #lifesciencesvision #mhra #nhs #oncology 
#r&d #respiratorydisease #vaccine

PRICENTRIC BRIEF:

  • The United Kingdom’s Life Science Vision 10-year strategy foresees the sector building on the successful response to the COVID-19 pandemic, with £1 billion in funding available to the UK’s most promising life sciences companies to approach solving major healthcare problems, including cancer and dementia
  • The Vision outlines seven critical healthcare missions for the government, industry, NHS, academia, and medical research charities to follow to prevent, diagnose, monitor, and treat diseases early, use innovative clinical trials to develop breakthrough products and treatments, and accelerate the development and adoption of new drugs, diagnostics, medical technology, and tools
  • The seven missions are 1) accelerating the pace of studies into novel dementia treatment, 2) enabling early diagnosis and treatments, including immune therapies such as cancer vaccines, 3) sustaining the UK’s position in vaccine discovery, development and manufacturing, 4) treatment and prevention of cardiovascular diseases and its major risk factors, including obesity, 5) reducing mortality and morbidity from respiratory disease in the UK and globally, 6) addressing the underlying biology of ageing, and 7) increasing the understanding of mental health conditions, including work to redefine diseases and develop tools to address them

THE DETAILS

LONDON, United Kingdom – The United Kingdom’s Life Science Vision 10-year strategy foresees the sector building on the successful response to the COVID-19 pandemic, with £1 billion in funding available to the UK’s most promising life sciences companies to approach solving major healthcare problems, including cancer and dementia.

The Vision outlines seven critical healthcare missions for the government, industry, NHS, academia, and medical research charities to follow to prevent, diagnose, monitor, and treat diseases early, use innovative clinical trials to develop breakthrough products and treatments, and accelerate the development and adoption of new drugs, diagnostics, medical technology, and tools.

The seven missions are:

  • Accelerating the pace of studies into novel dementia treatment
  • Enabling early diagnosis and treatments, including immune therapies such as cancer vaccines
  • Sustaining the UK’s position in vaccine discovery, development and manufacturing
  • Treatment and prevention of cardiovascular diseases and its major risk factors, including obesity
  • Reducing mortality and morbidity from respiratory disease in the UK and globally
  • Addressing the underlying biology of ageing
  • Increasing the understanding of mental health conditions, including work to redefine diseases and develop tools to address them

Under the plan, the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) will act as an independent, sovereign regulator with a focus on making sure vaccines, drugs, and technologies reach patients as swiftly as possible. Further, the Vision seeks to emulate the UK Vaccines Taskforce by harnessing private sector expertise and removing unnecessary bureaucratic boundaries.

Learn more about Pricentric ONE and our Global Pricing Solutions!

Contact us with your questions and global pricing needs, and an expert will follow up shortly.